• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

“不要忽视 Tau”:阿尔茨海默病和其他 Tau 病中针对 Tau 磷酸化的临床生物标志物和治疗方法的最新进展。

"Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies.

机构信息

Department of Neuroscience, College of Medicine, University of Florida, BMS J483/CTRND, 1275 Center Drive, Gainesville, FL, 32610, USA.

Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, Florida, 32610, USA.

出版信息

Mol Neurodegener. 2021 Jun 5;16(1):37. doi: 10.1186/s13024-021-00460-5.

DOI:10.1186/s13024-021-00460-5
PMID:34090488
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8180161/
Abstract

Phosphorylation is one of the most prevalent post-translational modifications found in aggregated tau isolated from Alzheimer's disease (AD) patient brains. In tauopathies like AD, increased phosphorylation or hyperphosphorylation can contribute to microtubule dysfunction and is associated with tau aggregation. In this review, we provide an overview of the structure and functions of tau protein as well as the physiologic roles of tau phosphorylation. We also extensively survey tau phosphorylation sites identified in brain tissue and cerebrospinal fluid from AD patients compared to age-matched healthy controls, which may serve as disease-specific biomarkers. Recently, new assays have been developed to measure minute amounts of specific forms of phosphorylated tau in both cerebrospinal fluid and plasma, which could potentially be useful for aiding clinical diagnosis and monitoring disease progression. Additionally, multiple therapies targeting phosphorylated tau are in various stages of clinical trials including kinase inhibitors, phosphatase activators, and tau immunotherapy. With promising early results, therapies that target phosphorylated tau  could be useful at slowing tau hyperphosphorylation and aggregation in AD and other tauopathies.

摘要

磷酸化是在阿尔茨海默病(AD)患者大脑中分离出的聚集态 tau 中发现的最普遍的翻译后修饰之一。在 AD 等tau 病中,磷酸化或过度磷酸化的增加可能导致微管功能障碍,并与 tau 聚集有关。在这篇综述中,我们概述了 tau 蛋白的结构和功能以及 tau 磷酸化的生理作用。我们还广泛调查了 AD 患者脑组织和脑脊液中与年龄匹配的健康对照组相比鉴定出的 tau 磷酸化位点,这些位点可能作为疾病特异性生物标志物。最近,已经开发出了新的测定法来测量脑脊液和血浆中特定形式的磷酸化 tau 的微量,这对于辅助临床诊断和监测疾病进展可能非常有用。此外,针对磷酸化 tau 的多种疗法正在不同的临床试验阶段,包括激酶抑制剂、磷酸酶激活剂和 tau 免疫疗法。由于早期结果令人鼓舞,针对磷酸化 tau 的疗法可能有助于减缓 AD 和其他 tau 病中的 tau 过度磷酸化和聚集。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e321/8180161/c23fe30f6b4d/13024_2021_460_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e321/8180161/3a81179d075b/13024_2021_460_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e321/8180161/1f2aee16f838/13024_2021_460_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e321/8180161/c23fe30f6b4d/13024_2021_460_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e321/8180161/3a81179d075b/13024_2021_460_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e321/8180161/1f2aee16f838/13024_2021_460_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e321/8180161/c23fe30f6b4d/13024_2021_460_Fig3_HTML.jpg

相似文献

1
"Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies.“不要忽视 Tau”:阿尔茨海默病和其他 Tau 病中针对 Tau 磷酸化的临床生物标志物和治疗方法的最新进展。
Mol Neurodegener. 2021 Jun 5;16(1):37. doi: 10.1186/s13024-021-00460-5.
2
Post-translational modifications of tau protein in Alzheimer's disease.阿尔茨海默病中tau蛋白的翻译后修饰
J Neural Transm (Vienna). 2005 Jun;112(6):813-38. doi: 10.1007/s00702-004-0221-0. Epub 2004 Oct 27.
3
A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer's disease.一种新的人类 Tau 非聚集性剪接异构体在阿尔茨海默病中减少。
Acta Neuropathol. 2021 Jul;142(1):159-177. doi: 10.1007/s00401-021-02317-z. Epub 2021 May 2.
4
PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.PTI-125 降低阿尔茨海默病患者的生物标志物。
J Prev Alzheimers Dis. 2020;7(4):256-264. doi: 10.14283/jpad.2020.6.
5
Novel aspects of the phosphorylation and structure of pathological tau: implications for tauopathy biomarkers.病理性tau蛋白磷酸化和结构的新特点:对tau蛋白病生物标志物的意义
FEBS Open Bio. 2024 Feb;14(2):181-193. doi: 10.1002/2211-5463.13667. Epub 2023 Jul 8.
6
A current view on Tau protein phosphorylation in Alzheimer's disease.阿尔茨海默病中 Tau 蛋白磷酸化的最新观点。
Curr Opin Neurobiol. 2021 Aug;69:131-138. doi: 10.1016/j.conb.2021.03.003. Epub 2021 Apr 21.
7
Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies.tau 丝氨酸 208 位磷酸化促进聚集,并揭示阿尔茨海默病和其他 tau 病中的神经病理学多样性。
Acta Neuropathol Commun. 2020 Jun 22;8(1):88. doi: 10.1186/s40478-020-00967-w.
8
Tau phosphorylation and aggregation in Alzheimer's disease pathology.阿尔茨海默病病理学中的tau蛋白磷酸化与聚集
FEBS Lett. 2006 May 22;580(12):2922-7. doi: 10.1016/j.febslet.2006.02.067. Epub 2006 Mar 3.
9
Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau).采用与 tau 构象选择性结合的抗 tau 单克隆抗体检测共病额颞叶变性-tau(FTLD-tau)中的阿尔茨海默病(AD)特异性 tau 病理学。
Acta Neuropathol Commun. 2019 Mar 4;7(1):34. doi: 10.1186/s40478-019-0687-5.
10
A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.一种新型 TAO 激酶抑制剂可减少与神经退行性变相关的人 tau 病中 tau 磷酸化位点的磷酸化。
Acta Neuropathol Commun. 2018 May 7;6(1):37. doi: 10.1186/s40478-018-0539-8.

引用本文的文献

1
Tauopathies: Calmodulin Regulates Tau Hyperphosphorylation and Its Transformation into Disease-Specific Aggregates.tau蛋白病:钙调蛋白调节tau蛋白的过度磷酸化及其向疾病特异性聚集体的转变。
Biomolecules. 2025 Aug 6;15(8):1133. doi: 10.3390/biom15081133.
2
Tau and tauopathies across primate species: implications for modeling neurodegenerative disorders.跨灵长类物种的tau蛋白与tau蛋白病:对神经退行性疾病建模的启示
Front Aging Neurosci. 2025 Jul 23;17:1598245. doi: 10.3389/fnagi.2025.1598245. eCollection 2025.
3
Interplay Between Aging and Tau Pathology in Alzheimer's Disease: Mechanisms and Translational Perspectives.

本文引用的文献

1
Tau antibody isotype induces differential effects following passive immunisation of tau transgenic mice.Tau 抗体亚型通过被动免疫 tau 转基因小鼠引起不同的影响。
Acta Neuropathol Commun. 2021 Mar 12;9(1):42. doi: 10.1186/s40478-021-01147-0.
2
Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.阿尔茨海默病中血液磷酸化 tau181 和神经丝轻链与神经退行性变的纵向关联。
JAMA Neurol. 2021 Apr 1;78(4):396-406. doi: 10.1001/jamaneurol.2020.4986.
3
Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis.
阿尔茨海默病中衰老与 Tau 病理的相互作用:机制与转化视角
Antioxidants (Basel). 2025 Jun 24;14(7):774. doi: 10.3390/antiox14070774.
4
A novel pThr217 tau monoclonal antibody reveals neuropathological heterogeneity in tauopathies.一种新型的磷酸化苏氨酸217 tau单克隆抗体揭示了tau蛋白病中的神经病理学异质性。
Sci Rep. 2025 Jun 5;15(1):19865. doi: 10.1038/s41598-025-04291-y.
5
Recent Advances in Mass Spectrometry-Based Studies of Post-Translational Modifications in Alzheimer's Disease.基于质谱的阿尔茨海默病翻译后修饰研究的最新进展
Mol Cell Proteomics. 2025 May 29;24(7):101003. doi: 10.1016/j.mcpro.2025.101003.
6
Tau-targeting nanoparticles for treatment of Alzheimer's disease.用于治疗阿尔茨海默病的靶向tau蛋白纳米颗粒。
Exploration (Beijing). 2024 Jun 21;5(2):20230137. doi: 10.1002/EXP.20230137. eCollection 2025 Apr.
7
Antisense oligonucleotides directed against App and Rab5 normalized endosomal Rab activity and reversed DS-AD-linked degenerative phenotypes in the Dp16 mouse model of Down syndrome.针对App和Rab5的反义寡核苷酸使内体Rab活性正常化,并逆转了唐氏综合征Dp16小鼠模型中与DS-AD相关的退化表型。
Alzheimers Dement. 2025 May;21(5):e70022. doi: 10.1002/alz.70022.
8
A pathological phosphorylation pattern enhances tau cooperativity on microtubules and facilitates tau filament assembly.病理性磷酸化模式增强了tau蛋白在微管上的协同作用,并促进tau蛋白丝的组装。
Res Sq. 2025 Apr 10:rs.3.rs-6247226. doi: 10.21203/rs.3.rs-6247226/v1.
9
Transthyretin as a therapeutic target: the future of disease-modifying therapies for Alzheimer's disease.转甲状腺素蛋白作为治疗靶点:阿尔茨海默病疾病修饰疗法的未来
Mol Biol Rep. 2025 Apr 8;52(1):370. doi: 10.1007/s11033-025-10485-4.
10
Early Alzheimer's Disease with frequent neuritic plaques harbors neocortical tau seeds distinct from primary age-related tauopathy.伴有频繁神经炎性斑块的早期阿尔茨海默病存在与原发性年龄相关性tau病不同的新皮质tau种子。
Nat Commun. 2025 Feb 21;16(1):1851. doi: 10.1038/s41467-025-56469-7.
用于阿尔茨海默病诊断的 CSF 磷酸化 tau T181 和 T217 生物标志物的临床性能的头对头比较。
Alzheimers Dement. 2021 May;17(5):755-767. doi: 10.1002/alz.12236. Epub 2020 Nov 30.
4
A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia.一项关于硒酸钠作为行为变异型额颞叶痴呆疾病修饰治疗的II期随机、双盲、安慰剂对照试验的研究方案。
BMJ Open. 2020 Nov 16;10(11):e040100. doi: 10.1136/bmjopen-2020-040100.
5
Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease.tau 修饰谱可识别患者异质性和阿尔茨海默病的阶段。
Cell. 2020 Dec 10;183(6):1699-1713.e13. doi: 10.1016/j.cell.2020.10.029. Epub 2020 Nov 13.
6
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected.在阿尔茨海默病临床前连续体的早期阶段,当仅检测到 Aβ 病理学的细微变化时,磷酸化的新型 tau 生物标志物在 T181、T217 或 T231 处升高。
EMBO Mol Med. 2020 Dec 7;12(12):e12921. doi: 10.15252/emmm.202012921. Epub 2020 Nov 10.
7
Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease.血浆磷酸化 Tau217 水平与早期阿尔茨海默病 Tau 正电子发射断层扫描的相关性。
JAMA Neurol. 2021 Feb 1;78(2):149-156. doi: 10.1001/jamaneurol.2020.4201.
8
Chronic Sodium Selenate Treatment Restores Deficits in Cognition and Synaptic Plasticity in a Murine Model of Tauopathy.慢性硒酸钠治疗可恢复tau蛋白病小鼠模型中的认知和突触可塑性缺陷。
Front Mol Neurosci. 2020 Oct 8;13:570223. doi: 10.3389/fnmol.2020.570223. eCollection 2020.
9
Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes.靶向细胞质或分泌途径的抗 tau scFv 可变地修饰病理学和神经退行性表型。
Mol Ther. 2021 Feb 3;29(2):859-872. doi: 10.1016/j.ymthe.2020.10.007. Epub 2020 Oct 14.
10
Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias.评估一种新型免疫分析法检测脑脊液中 p-tau Thr217,以区分阿尔茨海默病与其他类型痴呆。
Neurology. 2020 Dec 1;95(22):e3026-e3035. doi: 10.1212/WNL.0000000000010814. Epub 2020 Sep 24.